Therefore, it would be conceivable to hypothesize that, as for NASH, a multiple target therapeutic strategy should be tested in ALD, taking into account the possibility of intervening simultaneously on bile acid system, FGF15 and GLP-1 signaling, intestinal barrier, liver mitochondria, and others. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.